Almonertinib was approved for the treatment of patients with advanced NSCLC following progression on prior EGFR-TKIs and having a T790M drug-resistance mutation by the National Medical Products Administration (NMPA) in 2020 (Lu et al., 2021). Here, EGFR is linked to non-small cell lung carcinoma.